Denecimig - Novo Nordisk
Alternative Names: Coagulation factor VIII mimetic antibody - Novo Nordisk; FVIII mimetic antibody - Novo Nordisk; Mim-8; NN 7769; NN0365-3769; NNC0365-3769; NNC0365-3769 ALatest Information Update: 30 Jun 2025
At a glance
- Originator Novo Nordisk
- Developer Genmab; Novo Nordisk
- Class Antihaemorrhagics; Bispecific antibodies
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemophilia A
Most Recent Events
- 22 Jun 2025 Adverse events data from a phase IIIb FRONTIER 5 trial in Haemophilia A released by Novo Nordisk
- 22 Jun 2025 Efficacy and Adverse events data from the phase IIIb FRONTIER5 trial in Haemophilia A released by Novo Nordisk
- 07 Feb 2025 Novo Nordisk plans to submit regulatory application to US and EU for denecimig in Hemophilia A in 2025